ClinicalTrials.gg
RecruitingNCT06416293WAVESUpdated Apr 29, 2026

Widening Aims and Giving Patients a Voice for Expanded Structures in Breast Cancer Care Jointly Developed by Patients and Physicians

An observational study in Breast Cancer, sponsored by University Hospital Augsburg. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-29.

Sponsored by University Hospital Augsburg · Observational

How we know

From the registry’s dates

  • Started Apr 2022; still recruiting 4 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
2,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 678 studies in Breast Neoplasms with a site in Germany — 114 open to participants now, 196 under way, 81 of them phase 3. Breast Neoplasms · Germany.

Planned enrollment
20th of 92
2,000 · median 580
Started
2022
with 30 others
Observational
93 of 678
23 open now
Primary completion
2026-12
later than 63 of 195 live
Registered
610th of 678
by date

Among the 678 studies in Breast Neoplasms with a site in Germany, this one is the 20th largest by planned enrollment of the 92 observational ones that give a count, is one of 31 that started in 2022, is one of 93 observational ones, reaches primary completion later than 63 of the 195 other live ones, and was the 610th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

114 of the 678 studies in Breast Neoplasms with a site in Germany are open now. Recruiting first, the newest first:

109 more — sign in →

All 114 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 678 studies in Breast Neoplasms with a site in Germany, or all of them as a file.
02

Study summary

The aim of this BZKF project is to record the current care structure for breast cancer patients in order to use this as a basis for developing possible future models for improvement. The active involvement of representatives of regional and national patient organizations in the creation of a patient-based and patient-oriented survey ensures that the needs of patients are the focus. In addition to and in contrast to other projects, relevant questions are explicitly addressed not only to patients but also to physicians in order to identify and specify the interfaces between patient wishes/suggestions and to develop clinical consequences for care.

The first objective is to survey the "current situation" by recording the current care structure for breast cancer. The focus is on the survey of both groups on patient-physician communication, time management and coping strategies.

By planning the future harmonization of national data structures, the basis is created for the long-term goal of an improved "target", a concept developed jointly by physicians and patients for an improved communication and care structure that focuses on the patient.

03

Conditions studied

  • Breast Cancer

Keywords

  • Communication
  • patient-physician-relationship
  • questionnaire
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Women and men aged 18 years and older with breast cancer. Physicians treating breast cancer patients.

Eligibility criteria

Inclusion Criteria (patients):

  • Breast cancer or DCIS
  • women and men aged 18 years and older

Exclusion Criteria (patients):

  • women and men \< 18 years
  • no confirmed breast cancer or DCIS diagnosis

Inclusion Criteria (physicians):

- Treatment of breast cancer patients

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
2,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • BC Patients

    Patients with diagnosis of breast cancer or DCIS

    Other: Questionnaire patients

  • Physicians

    Physicians treating patients with breast cancer

    Other: Questionnaire physicians

Interventions

  • OtherQuestionnaire patients

    Completion of a two-part questionnaire with a special focus on communication around the breast cancer diagnosis. Tumor stage and therapies received are also surveyed. The questionnaire can be answered online via a secure tool (REDCap) or in paper form.

  • OtherQuestionnaire physicians

    Completion of a questionnaire with a special focus on communication around the breast cancer diagnosis

06

What researchers measure

Primary outcomes

  1. Current state of care - patient view

    The primary aim of the questionnaire is to record the current reality of care for breast cancer patients with a focus on communication.

    Time frame: through study completion, an average of 3 years

Secondary outcomes

  1. Current state of care - physician view

    Secondarily, a comparison will be made with the physicians assessment of the same topics

    Time frame: through study completion, an average of 3 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2022 (actual). Primary completion is estimated for Dec 2026, 56 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2024
First posted
May 16, 2024
StartActual
Apr 1, 2022
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Apr 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06416293
Lead sponsor
University Hospital Augsburg
Collaborators
Wuerzburg University Hospital, Technical University of Munich, LMU Klinikum, University Hospital Regensburg, University Hospital Erlangen, Bavarian Cancer Research Center (BZKF)
Responsible party
Nina Ditsch (Head of Breast Centre University Hospital Augsburg, Principal Investigator, Clinical Professor, University Hospital Augsburg) — Principal investigator
First posted
May 16, 2024
Start date
Apr 1, 2022
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Apr 29, 2026

Study contacts

Nina Ditsch, Prof.
Contact
nina.ditsch@uk-augsburg.de
+49 821 400 15809
Melitta Köpke, Dr.
Contact
melitta.koepke@uk-augsburg.de
+49 821 400 165862
Nina Ditsch, Prof.
principal investigator · University Hospital Augsburg

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion